Active Surveillance for Norovirus in a US Veterans Affairs Patient Population, Houston, Texas, 2015-2016.

acute gastroenteritis burden norovirus veterans

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 02 01 2019
accepted: 01 03 2019
entrez: 6 4 2019
pubmed: 6 4 2019
medline: 6 4 2019
Statut: epublish

Résumé

Norovirus is a leading cause of acute gastroenteritis (AGE); however, few data exist on endemic norovirus disease burden among adults. Candidate norovirus vaccines are currently in development for all ages, and robust estimates of norovirus incidence among adults are needed to provide baseline data. We conducted active surveillance for AGE among inpatients at a Veterans Affairs (VA) hospital in Houston, Texas. Patients with AGE (≥3 loose stools, ≥2 vomiting episodes, or ≥1 episode of both loose stool and vomiting, within 24 hours) within 10 days of enrollment and non-AGE control patients were enrolled. Demographic data and clinical characteristics were collected. Stool samples were tested using the FilmArray gastrointestinal panel; virus-positives were confirmed by real-time reverse transcription polymerase chain reaction and genotyped by sequencing. From November 2, 2015 through November 30, 2016, 147 case patients and 19 control patients were enrolled and provided a stool specimen. Among case patients, 139 (95%) were male and 70 (48%) were aged ≥65 years. Norovirus was the leading viral pathogen detected (in 16 of 20 virus-positive case patients) and accounted for 11% of all AGE cases. No viral pathogens were detected among control patients. Incidence of norovirus-associated hospitalization was 20.3 cases/100 000 person-years and was similar among those aged <65 and ≥65 years. This active surveillance platform employed screening and enrollment of hospitalized VA patients meeting a standardized AGE case definition, as well as non-AGE control patients. Data from this study highlight the burden of norovirus in a VA inpatient population and will be useful in policy considerations of a norovirus vaccine.

Sections du résumé

BACKGROUND BACKGROUND
Norovirus is a leading cause of acute gastroenteritis (AGE); however, few data exist on endemic norovirus disease burden among adults. Candidate norovirus vaccines are currently in development for all ages, and robust estimates of norovirus incidence among adults are needed to provide baseline data.
METHODS METHODS
We conducted active surveillance for AGE among inpatients at a Veterans Affairs (VA) hospital in Houston, Texas. Patients with AGE (≥3 loose stools, ≥2 vomiting episodes, or ≥1 episode of both loose stool and vomiting, within 24 hours) within 10 days of enrollment and non-AGE control patients were enrolled. Demographic data and clinical characteristics were collected. Stool samples were tested using the FilmArray gastrointestinal panel; virus-positives were confirmed by real-time reverse transcription polymerase chain reaction and genotyped by sequencing.
RESULTS RESULTS
From November 2, 2015 through November 30, 2016, 147 case patients and 19 control patients were enrolled and provided a stool specimen. Among case patients, 139 (95%) were male and 70 (48%) were aged ≥65 years. Norovirus was the leading viral pathogen detected (in 16 of 20 virus-positive case patients) and accounted for 11% of all AGE cases. No viral pathogens were detected among control patients. Incidence of norovirus-associated hospitalization was 20.3 cases/100 000 person-years and was similar among those aged <65 and ≥65 years.
CONCLUSIONS CONCLUSIONS
This active surveillance platform employed screening and enrollment of hospitalized VA patients meeting a standardized AGE case definition, as well as non-AGE control patients. Data from this study highlight the burden of norovirus in a VA inpatient population and will be useful in policy considerations of a norovirus vaccine.

Identifiants

pubmed: 30949545
doi: 10.1093/ofid/ofz115
pii: ofz115
pmc: PMC6441783
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofz115

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI057788
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM124280
Pays : United States

Références

Clin Infect Dis. 2002 Aug 1;35(3):246-53
pubmed: 12115089
Emerg Infect Dis. 2003 Dec;9(12):1563-70
pubmed: 14720397
Clin Infect Dis. 2004 Aug 1;39(3):318-24
pubmed: 15306997
Emerg Infect Dis. 2008 Oct;14(10):1553-7
pubmed: 18826818
J Clin Microbiol. 2010 Jan;48(1):168-77
pubmed: 19864482
Epidemiol Infect. 2010 Oct;138(10):1454-8
pubmed: 20196905
J Infect Dis. 2010 Jun 1;201(11):1617-24
pubmed: 20402596
Epidemiol Infect. 2011 Nov;139(11):1676-86
pubmed: 21205382
Clin Infect Dis. 2011 Feb 15;52(4):466-74
pubmed: 21258098
Emerg Infect Dis. 2011 Aug;17(8):1381-8
pubmed: 21801613
Clin Infect Dis. 2011 Sep;53(6):568-71
pubmed: 21832262
J Infect Dis. 2013 Apr;207(7):1058-65
pubmed: 23300161
Eur J Pediatr. 2013 Jun;172(6):739-46
pubmed: 23361964
N Engl J Med. 2013 Mar 21;368(12):1121-30
pubmed: 23514289
J Infect Dis. 2013 Sep 1;208(5):790-800
pubmed: 23757337
Emerg Infect Dis. 2013 Aug;19(8):1198-205
pubmed: 23876403
Emerg Infect Dis. 2013 Aug;19(8):1214-21
pubmed: 23876432
PLoS One. 2013 Oct 02;8(10):e75922
pubmed: 24098406
PLoS One. 2014 May 21;9(5):e98201
pubmed: 24849288
J Clin Microbiol. 2015 Feb;53(2):373-81
pubmed: 24989606
J Infect Dis. 2015 Mar 15;211(6):870-8
pubmed: 25210140
PLoS One. 2015 May 21;10(5):e0126733
pubmed: 25996826
MMWR Surveill Summ. 2015 Dec 11;64(12):1-16
pubmed: 26656915
PLoS One. 2016 Apr 26;11(4):e0148395
pubmed: 27115485
PLoS One. 2016 Apr 26;11(4):e0148505
pubmed: 27115602
J Clin Microbiol. 2017 Jul;55(7):2208-2221
pubmed: 28490488
Clin Ther. 2017 Aug;39(8):1537-1549
pubmed: 28756066
Infect Dis Clin North Am. 2017 Dec;31(4):839-870
pubmed: 28911830
Am J Public Health. 1982 Dec;72(12):1329-32
pubmed: 6291414
J Infect Dis. 1994 Jul;170(1):34-43
pubmed: 8014518

Auteurs

Anita K Kambhampati (AK)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
IHRC, Inc., Atlanta, Georgia.

Blanca Vargas (B)

Infectious Diseases Section, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
Infectious Diseases Section, Baylor College of Medicine, Houston, Texas.

Mahwish Mushtaq (M)

Infectious Diseases Section, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
Infectious Diseases Section, Baylor College of Medicine, Houston, Texas.

Hannah Browne (H)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee.

Scott Grytdal (S)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Robert L Atmar (RL)

Infectious Diseases Section, Baylor College of Medicine, Houston, Texas.

Jan Vinjé (J)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Umesh D Parashar (UD)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Benjamin Lopman (B)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Rollins School of Public Health, Emory University, Atlanta, Georgia.

Aron J Hall (AJ)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Maria C Rodriguez-Barradas (MC)

Infectious Diseases Section, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
Infectious Diseases Section, Baylor College of Medicine, Houston, Texas.

Cristina V Cardemil (CV)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Classifications MeSH